Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-026040
Filing Date
2021-05-10
Accepted
2021-05-10 16:06:22
Documents
53
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q stok-10q_20210331.htm 10-Q 1621454
2 EX-31.1 stok-ex311_12.htm EX-31.1 17396
3 EX-31.2 stok-ex312_8.htm EX-31.2 17576
4 EX-32.1 stok-ex321_14.htm EX-32.1 7196
5 EX-32.2 stok-ex322_6.htm EX-32.2 7869
  Complete submission text file 0001564590-21-026040.txt   4239069

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT stok-20210331.xml EX-101.INS 626805
7 XBRL TAXONOMY EXTENSION SCHEMA stok-20210331.xsd EX-101.SCH 38800
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE stok-20210331_cal.xml EX-101.CAL 33880
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE stok-20210331_def.xml EX-101.DEF 73637
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE stok-20210331_lab.xml EX-101.LAB 257512
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stok-20210331_pre.xml EX-101.PRE 183893
Mailing Address 3 PRESTON COURT BEDFORD MA 01730
Business Address 3 PRESTON COURT BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38938 | Film No.: 21907173
SIC: 2834 Pharmaceutical Preparations